FOXO6

Summary

FOXO6 (forkhead box O6, HGNC:24814) is a protein-coding gene on chromosome 1p34.2, encoding Forkhead box protein O6 (A8MYZ6). Transcriptional activator.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in positive regulation of dendritic spine development and regulation of transcription by RNA polymerase II. Predicted to be located in chromatin and cytoplasm. Predicted to be active in nucleus.

Source: NCBI Gene 100132074 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_001291281

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24814
Approved symbol	FOXO6
Name	forkhead box O6
Location	1p34.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000204060
Ensembl biotype	protein_coding
OMIM	611457
Entrez	100132074

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000372591, ENST00000641094, ENST00000686812

RefSeq mRNA: 1 — MANE Select: NM_001291281 NM_001291281

Canonical transcript exons

ENST00000641094 — 3 exons

Exon	Start	End
ENSE00003812603	41361931	41362344
ENSE00003814052	41381616	41382200
ENSE00003814105	41382202	41382681

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 89.78.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4381 / max 93.3204, expressed in 745 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
2424	2.4381	745

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	89.78	gold quality
ganglionic eminence	UBERON:0004023	83.25	gold quality
pituitary gland	UBERON:0000007	79.88	gold quality
adenohypophysis	UBERON:0002196	79.26	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.71	gold quality
hindlimb stylopod muscle	UBERON:0004252	73.93	gold quality
right ovary	UBERON:0002118	72.39	gold quality
left ovary	UBERON:0002119	72.24	gold quality
ovary	UBERON:0000992	71.93	gold quality
left lobe of thyroid gland	UBERON:0001120	70.66	gold quality
body of uterus	UBERON:0009853	70.50	gold quality
placenta	UBERON:0001987	70.30	gold quality
Ammon’s horn	UBERON:0001954	69.81	gold quality
thyroid gland	UBERON:0002046	69.67	gold quality
left uterine tube	UBERON:0001303	69.61	gold quality
nucleus accumbens	UBERON:0001882	69.53	gold quality
skeletal muscle tissue	UBERON:0001134	69.31	gold quality
right lobe of thyroid gland	UBERON:0001119	69.26	gold quality
hypothalamus	UBERON:0001898	68.73	gold quality
putamen	UBERON:0001874	68.54	gold quality
caudate nucleus	UBERON:0001873	67.76	gold quality
ventricular zone	UBERON:0003053	67.61	gold quality
ascending aorta	UBERON:0001496	67.44	gold quality
thoracic aorta	UBERON:0001515	67.19	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.90	gold quality
anterior cingulate cortex	UBERON:0009835	66.61	gold quality
gastrocnemius	UBERON:0001388	66.43	gold quality
myometrium	UBERON:0001296	66.29	gold quality
muscle of leg	UBERON:0001383	66.14	gold quality
popliteal artery	UBERON:0002250	66.09	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

5 targets.

Target	Regulation
FBXO32	Activation
IDH1	Unknown
MYC	Activation
PPARGC1A	Unknown
TRIM63	Activation

JASPAR motifs

Motif	Name	Family
MA0849.1	FOXO6	FOX

JASPAR matrix evidence (PMIDs): PMID:10880363

Upstream regulators (CollecTRI, top): NFIA, NFIB, NFIX

miRNA regulators (miRDB)

40 targeting FOXO6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-363-5P	99.46	64.51	1015
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-5583-3P	99.06	65.68	1018
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-6871-5P	98.90	66.67	671

Literature-anchored findings (GeneRIF, showing 20)

• cloning and characterization; structural and functional properties related to gene regulation (PMID:12857750)
• gene study of FOXO6, reveals no association with human longevity in Germans (PMID:21388494)
• Studies indictet that the mammalian FoxO family consists of FoxO1, 3, 4 and 6 and are regulated by by AKT and 14-3-3 proteins. (PMID:21708191)
• investigation of role of FoxO6 in liver: Data suggest that a FoxO6-dependent pathway in hepatocytes orchestrates insulin regulation of gluconeogenesis. (PMID:21940782)
• Studies indicate that FoxO6 is produced in the liver of both rodents and humans. (PMID:23324123)
• FOXO6 induces C-myc expression by associating to HNF4 and mediating histone acetylation, and the dissociation of HDAC3 from the promoter of the C-myc gene (PMID:23714368)
• In conclusion, the results of the present study indicated that the FOXO6/USP7 molecular network has an important role in the regulation of lung cancer development. (PMID:25695151)
• Lacking the FOXO6 risk allele was associated with an increase in negative schizophrenia symptoms and surface area reduction in the right orbitofrontal gyrus - an area previously associated with negative symptoms - suggesting that presence of the FOXO6 risk allele confers resistance against negative symptoms and associated neuroanatomical changes in individuals with first-episode schizophrenia. (PMID:28234206)
• this study established a correlation between FOXO6 expression and gastric cancer prognosis. FOXO6 could be a promising predictor for prognosis in gastric cancer. (PMID:28404958)
• The results indicated that FOXO6 knockdown inhibited colorectal cancer cell proliferation, migration, invasion, and glycolysis via the PI3K/Akt/mTOR pathway. (PMID:30321450)
• High FOXO6 expression is associated with gastric cancer. (PMID:30453063)
• suppression of FOXO6 protects ARPE-19 cells from HG-induced oxidative stress and apoptosis, which is in part mediated by the activation of Akt/Nrf2 pathway. (PMID:30548643)
• downstream effector in 5-HT1D-induced hepatocellular carcinoma progression (PMID:30561038)
• FoxO6 regulated nuclear factor erythroid 2-related factor (Nrf2) expression via c-Myc after 3% isoflurane preconditioning and OGD exposure. Thus, isoflurane preconditioning prevented OGD-induced injury in LO2 cells by modulating FoxO6, c-Myc, and Nrf2 signaling. (PMID:31894125)
• Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation. (PMID:32639626)
• Downregulation of FOXO6 alleviates hypoxia-induced apoptosis and oxidative stress in cardiomyocytes by enhancing Nrf2 activation via upregulation of SIRT6. (PMID:33123950)
• Association of genetic variants of FBXO32 and FOXO6 in the FOXO pathway with breast cancer risk. (PMID:34197655)
• LncRNA HOXC-AS1 promotes nasopharyngeal carcinoma (NPC) progression by sponging miR-4651 and subsequently upregulating FOXO6. (PMID:34507637)
• Upregulation of FoxO6 in nucleus pulposus cells promotes DNA damage repair via activation of RAD51. (PMID:34533813)
• FOXO6 transcription inhibition of CTRP3 promotes OGD/R-triggered cardiac microvascular endothelial barrier disruption via SIRT1/Nrf2 signalling. (PMID:36688407)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	foxo3a	ENSDARG00000023058
danio_rerio	foxo3b	ENSDARG00000042904
mus_musculus	Foxo6	ENSMUSG00000052135
rattus_norvegicus	Foxo6	ENSRNOG00000032639

Paralogs (41): FOXP3 (ENSG00000049768), FOXC1 (ENSG00000054598), FOXJ2 (ENSG00000065970), FOXF1 (ENSG00000103241), FOXN1 (ENSG00000109101), FOXM1 (ENSG00000111206), FOXP1 (ENSG00000114861), FOXO3 (ENSG00000118689), FOXA2 (ENSG00000125798), FOXA1 (ENSG00000129514), FOXJ1 (ENSG00000129654), FOXK2 (ENSG00000141568), FOXO1 (ENSG00000150907), FOXH1 (ENSG00000160973), FOXQ1 (ENSG00000164379), FOXK1 (ENSG00000164916), FOXD4 (ENSG00000170122), FOXA3 (ENSG00000170608), FOXB1 (ENSG00000171956), FOXR1 (ENSG00000176302), FOXL1 (ENSG00000176678), FOXC2 (ENSG00000176692), FOXE1 (ENSG00000178919), FOXS1 (ENSG00000179772), FOXL2 (ENSG00000183770), FOXO4 (ENSG00000184481), FOXD4L1 (ENSG00000184492), FOXD4L4 (ENSG00000184659), FOXD2 (ENSG00000186564), FOXI2 (ENSG00000186766), FOXE3 (ENSG00000186790), FOXD3 (ENSG00000187140), FOXD4L3 (ENSG00000187559), FOXR2 (ENSG00000189299), FOXJ3 (ENSG00000198815), FOXB2 (ENSG00000204612), FOXD4L5 (ENSG00000204779), FOXI3 (ENSG00000214336), FOXL3 (ENSG00000248767), FOXD1 (ENSG00000251493)

Protein

Protein identifiers

Forkhead box protein O6 — A8MYZ6 (reviewed: A8MYZ6)

All UniProt accessions (2): A0A8I5QKU9, A8MYZ6

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional activator.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Phosphorylation of Ser-184 is be important in regulating the transacriptional activity.

RefSeq proteins (1): NP_001278210* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001766	Fork_head_dom	Domain
IPR030456	TF_fork_head_CS_2	Conserved_site
IPR032067	FOXO-TAD	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR047410	FH_FOXO6	Domain

Pfam: PF00250, PF16676

UniProt features (10 total): region of interest 4, compositionally biased region 3, chain 1, DNA-binding region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A8MYZ6-F1	58.32	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 184

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-198693	AKT phosphorylates targets in the nucleus
R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-9614399	Regulation of localization of FOXO transcription factors
R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes

MSigDB gene sets: 62 (showing top): GOBP_DENDRITE_DEVELOPMENT, GOBP_MEMORY, GOBP_COGNITION, GOBP_BEHAVIOR, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_DENDRITIC_SPINE_DEVELOPMENT, chr1p34, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, LIAO_METASTASIS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_CELL_PROJECTION_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GOBP_POSITIVE_REGULATION_OF_DENDRITIC_SPINE_DEVELOPMENT, SENESE_HDAC3_TARGETS_DN

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), memory (GO:0007613), positive regulation of dendritic spine development (GO:0060999), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), beta-catenin binding (GO:0008013), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
FOXO-mediated transcription	2
PIP3 activates AKT signaling	1
PI3K/AKT Signaling in Cancer	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
learning or memory	1
positive regulation of developmental process	1
dendritic spine development	1
regulation of dendritic spine development	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
protein binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
DNA binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1030 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FOXO6	AKT1	P31749	629
FOXO6	IGF1	P01343	566
FOXO6	SIRT1	Q96EB6	557
FOXO6	SGK1	O00141	518
FOXO6	BCL2L11	O43521	505
FOXO6	INS	P01308	497
FOXO6	PTEN	P60484	423
FOXO6	F5H3C5	F5H3C5	421
FOXO6	SOD2	P04179	421
FOXO6	G6PC1	P35575	415
FOXO6	MTOR	P42345	400
FOXO6	SIRT6	Q8N6T7	391
FOXO6	CDKN1B	P46527	383
FOXO6	UBE2QL1	A1L167	383
FOXO6	SESN3	P58005	369

IntAct

12 interactions, top by confidence:

A	B	Type	Score
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
FOXO6	HNF4A	psi-mi:“MI:0915”(physical association)	0.400
HNF4A	FOXO6	psi-mi:“MI:0915”(physical association)	0.400
FOXO6		psi-mi:“MI:0914”(association)	0.350
FOXO3	FOXO6	psi-mi:“MI:0914”(association)	0.350
FOXO6	FOXO6	psi-mi:“MI:0914”(association)	0.350
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: A0A8I6AGW3, A2A9A2, A6NMB9, A8MYZ6, E9PZZ1, J3QK54, O02755, O02756, O35392, O35767, O60548, O70220, P05554, P17676, P21272, P28033, P35713, P42582, P49715, P49716, P52952, P53566, P58012, Q12952, Q13461, Q14526, Q60843, Q61345, Q63244, Q63250, Q6BEB4, Q6VFT5, Q6VFT6, Q6ZQN5, Q70KY4, Q8IU81, Q8MIP2, Q8NDY6, Q8R2I0, Q98937

Diamond homologs: A0A2Z4LIS9, A3RK74, A3RK75, A4L7N3, A8MYZ6, B3LYS5, B3P0K6, B4G4S8, B4HF64, B4JSC2, B4KBF6, B4MB78, B4NFR1, B4PTD3, E1BPQ1, G3V7R4, O16850, O43524, P0CG31, P23512, P32182, P32183, P32315, P33205, P33206, P35582, P35583, P35584, P55317, P55318, P84961, P98177, Q07342, Q10924, Q12778, Q28EM1, Q298W7, Q3Y598, Q4VUF1, Q63248

SIGNOR signaling

12 interactions.

A	Effect	B	Mechanism
AKT1	down-regulates	FOXO6	phosphorylation
CSNK1A1	down-regulates	FOXO6	phosphorylation
DYRK1A	down-regulates	FOXO6	phosphorylation
FOXO6	“up-regulates quantity by expression”	FBXO32	“transcriptional regulation”
FOXO6	“up-regulates quantity by expression”	TRIM63	“transcriptional regulation”
FOXO6	“up-regulates quantity by expression”	IDH1	“transcriptional regulation”
AKT	down-regulates	FOXO6	phosphorylation
NFIA	“down-regulates quantity”	FOXO6	“transcriptional regulation”
NFIB	“down-regulates quantity”	FOXO6	“transcriptional regulation”
NFIX	“down-regulates quantity”	FOXO6	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

458 predictions. Top by Δscore:

Variant	Effect	Δscore
1:41362309:GA:G	donor_gain	1.0000
1:41362341:G:GT	donor_gain	1.0000
1:41362342:A:T	donor_gain	1.0000
1:41362290:T:G	donor_gain	0.9900
1:41362342:AAG:A	donor_loss	0.9900
1:41362343:AGGT:A	donor_loss	0.9900
1:41362344:GG:G	donor_loss	0.9900
1:41362345:G:A	donor_loss	0.9900
1:41362346:T:A	donor_loss	0.9900
1:41381607:T:TA	acceptor_gain	0.9900
1:41381608:G:A	acceptor_gain	0.9900
1:41381610:CCACA:C	acceptor_loss	0.9900
1:41381611:CACA:C	acceptor_loss	0.9900
1:41381612:ACAGA:A	acceptor_loss	0.9900
1:41381613:C:G	acceptor_gain	0.9900
1:41381613:CAGAA:C	acceptor_loss	0.9900
1:41381614:A:AG	acceptor_gain	0.9900
1:41381614:A:AT	acceptor_loss	0.9900
1:41381615:G:GA	acceptor_gain	0.9900
1:41381615:G:T	acceptor_loss	0.9900
1:41381615:GA:G	acceptor_gain	0.9900
1:41381615:GAA:G	acceptor_gain	0.9900
1:41381615:GAAC:G	acceptor_gain	0.9900
1:41381615:GAACT:G	acceptor_gain	0.9900
1:41381601:T:TA	acceptor_gain	0.9800
1:41362317:C:T	donor_gain	0.9400
1:41374920:ACTC:A	acceptor_gain	0.9400
1:41362329:C:G	donor_gain	0.9300
1:41381612:A:AG	acceptor_gain	0.9300
1:41380591:C:T	donor_gain	0.9000

AlphaMissense

3138 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:41362009:T:A	W27R	1.000
1:41362009:T:C	W27R	1.000
1:41362186:A:G	N86D	1.000
1:41362187:A:T	N86I	1.000
1:41362188:C:A	N86K	1.000
1:41362188:C:G	N86K	1.000
1:41362192:T:A	W88R	1.000
1:41362192:T:C	W88R	1.000
1:41362193:G:C	W88S	1.000
1:41362193:G:T	W88L	1.000
1:41362194:G:C	W88C	1.000
1:41362194:G:T	W88C	1.000
1:41362195:G:A	G89R	1.000
1:41362195:G:C	G89R	1.000
1:41362195:G:T	G89W	1.000
1:41362196:G:A	G89E	1.000
1:41362196:G:C	G89A	1.000
1:41362196:G:T	G89V	1.000
1:41362202:T:C	L91P	1.000
1:41362205:C:A	S92Y	1.000
1:41362205:C:T	S92F	1.000
1:41362207:T:A	Y93N	1.000
1:41362207:T:C	Y93H	1.000
1:41362207:T:G	Y93D	1.000
1:41362208:A:G	Y93C	1.000
1:41362210:G:C	A94P	1.000
1:41362211:C:A	A94D	1.000
1:41362217:T:A	L96H	1.000
1:41362217:T:C	L96P	1.000
1:41362219:A:T	I97F	1.000

dbSNP variants (sampled 300 via entrez): RS1000024681 (1:41383494 C>G,T), RS1000042416 (1:41383764 A>G), RS1000070231 (1:41370773 C>T), RS1000176731 (1:41366056 C>A,G,T), RS1000228298 (1:41376524 C>G), RS1000251067 (1:41375738 T>C), RS1000304842 (1:41383353 G>A), RS1000356942 (1:41383610 G>A), RS1000411505 (1:41360171 G>A), RS1000448566 (1:41378972 C>A,T), RS1000661008 (1:41363587 A>G,T), RS1000782241 (1:41369264 G>A), RS1000793651 (1:41369528 G>C), RS1001448723 (1:41364263 G>A), RS1001580706 (1:41366483 C>T)

Disease associations

OMIM: gene MIM:611457 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST003542_104	Night sleep phenotypes	9.000000e-07
GCST004364_29	Intelligence	4.000000e-09
GCST004364_9	Intelligence	1.000000e-08
GCST005316_276	Intelligence (MTAG)	1.000000e-09
GCST005316_441	Intelligence (MTAG)	2.000000e-11
GCST005316_445	Intelligence (MTAG)	1.000000e-11
GCST005316_446	Intelligence (MTAG)	7.000000e-10
GCST006269_709	General cognitive ability	2.000000e-09
GCST006269_816	General cognitive ability	9.000000e-09
GCST006628_26	Systolic blood pressure	9.000000e-11
GCST007044_2	Extremely high intelligence	4.000000e-08
GCST007327_183	Smoking status (ever vs never smokers)	4.000000e-12
GCST008162_66	Hip circumference	7.000000e-07
GCST008595_4	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	1.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0006335	systolic blood pressure
EFO:0004318	smoking behavior
EFO:0004784	self reported educational attainment

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	increases expression	2
trichostatin A	decreases expression	1
beta-lapachone	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Estradiol	affects cotreatment, decreases expression	1
Methapyrilene	decreases methylation	1
Niclosamide	increases expression	1
Smoke	decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	increases expression	1
Lactic Acid	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.